Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells

Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review

(2018) Ricardo L. B. Costa et al.   BREAST CANCER RESEARCH AND TREATMENT

Metastatic and triple-negative breast cancer: challenges and treatment options

(2018) Sumayah Al-Mahmood et al.   Drug Delivery and Translational Research

Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going

(2018) Claudia Omarini et al.   Cancer Management and Research

Genetic Markers in Triple-Negative Breast Cancer

(2018) Zuzana Sporikova et al.   Clinical Breast Cancer

Anti-EGFR monoclonal antibodies enhance sensitivity to DNA-damaging agents in BRCA1 -mutated and PTEN -wild-type triple-negative breast cancer cells

(2017) Abderrahim El Guerrab et al.   MOLECULAR CARCINOGENESIS

FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer

(2016) D. Kazandjian et al.   CLINICAL CANCER RESEARCH

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer

(2016) Abderrahim El Guerrab et al.   Oncotarget

Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer

(2015) Andrea Gombos et al.   Expert Opinion on Drug Metabolism & Toxicology

Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer

(2015) Paolo Cossu-Rocca et al.   PLoS One

Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences

(2015) Mark Kriegsmann et al.   Oncotarget

Subtyping of triple-negative breast cancer: Implications for therapy

(2014) Vandana G. Abramson et al.   CANCER

Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds

(2013) YU HUANG et al.   ONCOLOGY REPORTS

Combination of mTOR and EGFR Kinase Inhibitors Blocks mTORC1 and mTORC2 Kinase Activity and Suppresses the Progression of Colorectal Carcinoma

(2013) Quan Wang et al.   PLoS One

Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors

(2012) Song Dong et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

mTOR Signaling in Growth Control and Disease

(2012) Mathieu Laplante et al.   CELL

The clonal and mutational evolution spectrum of primary triple-negative breast cancers

(2012) Sohrab P. Shah et al.   NATURE

Comprehensive molecular portraits of human breast tumours

(2012) Daniel C. Koboldt et al.   NATURE

Simultaneous targeting of EGFR and mTOR inhibits the growth of colorectal carcinoma cells

(2012) Chunhai Hao   ONCOLOGY REPORTS

Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

(2011) Matthias Scheffler et al.   CLINICAL PHARMACOKINETICS

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells

(2011) T. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Everolimus for Advanced Pancreatic Neuroendocrine Tumors

(2011) James C. Yao et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

(2010) Mothaffar F. Rimawi et al.   CANCER

Deciphering the Role of PI3K/Akt/mTOR Pathway in Breast Cancer Biology and Pathogenesis

(2010) Priscilla F. McAuliffe et al.   Clinical Breast Cancer

Triple-Negative Breast Cancer

(2010) William D. Foulkes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines

(2009) Silvia La Monica et al.   BIOCHEMICAL PHARMACOLOGY

PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

(2009) M. L. Sos et al.   CANCER RESEARCH

An Integrative Genomic and Proteomic Analysis of PIK3CA, PTEN, and AKT Mutations in Breast Cancer

(2008) K. Stemke-Hale et al.   CANCER RESEARCH

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

(2008) Arkaitz Carracedo et al.   JOURNAL OF CLINICAL INVESTIGATION

Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer

(2008) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

(2008) Robert J Motzer et al.   LANCET